Protein

Augusts 5, 2024

Carlos Colás: “Our studies have high social impact, but little investment attractiveness for the pharmaceutical industry”

The IIS Aragón researcher speaks in this interview about his work directing the Allergy Hospital Clínico Group (GIIS039), and what his projects are like.